Skip to Main content Skip to Navigation
Journal articles

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony Mato 1 Nirav Shah 2 Wojciech Jurczak 3 Chan Cheah 4 John Pagel 5 Jennifer Woyach 6 Bita Fakhri 7 Toby Eyre 8 Nicole Lamanna 9 Manish Patel 10 Alvaro Alencar 11 Ewa Lech-Maranda 12 William Wierda 13 Catherine Coombs 14 James Gerson 15 Paolo Ghia 16 Steven Le Gouill 17 David Lewis 18 Suchitra Sundaram 19 Jonathon Cohen 20 Ian Flinn 21 Constantine Tam 22, 23 Minal Barve 24 Bryone Kuss 25 Justin Taylor 11 Omar Abdel-Wahab 26 Stephen Schuster 15 Lia Palomba 26 Katharine Lewis 4 Lindsey Roeker 26 Matthew Davids 27, 28 Xuan Tan 4 Timothy Fenske 29 Johan Wallin 30 Donald Tsai 30 Nora Ku 30 Edward Zhu 30 Jessica Chen 30 Ming Yin 30 Binoj Nair 30 Kevin Ebata 30 Narasimha Marella 30 Jennifer Brown 27, 28 Michael Wang 31, *
* Corresponding author
17 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : Background: Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of pirtobrutinib (working name; formerly known as LOXO-305), a highly selective, reversible BTK inhibitor, in these patients. Methods: Patients with previously treated B-cell malignancies were enrolled in a first-in-human, multicentre, open-label, phase 1/2 trial of the BTK inhibitor pirtobrutinib. The primary endpoint was the maximum tolerated dose (phase 1) and overall response rate (ORR; phase 2). This trial is registered with ClinicalTrials.gov, NCT03740529. Findings: 323 patients were treated with pirtobrutinib across seven dose levels (25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg once per day) with linear dose-proportional exposures. No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. The recommended phase 2 dose was 200 mg daily. Adverse events in at least 10% of 323 patients were fatigue (65 [20%]), diarrhoea (55 [17%]), and contusion (42 [13%]). The most common adverse event of grade 3 or higher was neutropenia (32 [10%]). There was no correlation between pirtobrutinib exposure and the frequency of grade 3 treatment-related adverse events. Grade 3 atrial fibrillation or flutter was not observed, and grade 3 haemorrhage was observed in one patient in the setting of mechanical trauma. Five (1%) patients discontinued treatment due to a treatment-related adverse event. In 121 efficacy evaluable patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) treated with a previous covalent BTK inhibitor (median previous lines of treatment 4), the ORR with pirtobrutinib was 62% (95% CI 53-71). The ORR was similar in CLL patients with previous covalent BTK inhibitor resistance (53 [67%] of 79), covalent BTK inhibitor intolerance (22 [52%] of 42), BTK C481-mutant (17 [71%] of 24) and BTK wild-type (43 [66%] of 65) disease. In 52 efficacy evaluable patients with mantle cell lymphoma (MCL) previously treated with covalent BTK inhibitors, the ORR was 52% (95% CI 38-66). Of 117 patients with CLL, SLL, or MCL who responded, all but eight remain progression-free to date. Interpretation: Pirtobrutinib was safe and active in multiple B-cell malignancies, including patients previously treated with covalent BTK inhibitors. Pirtobrutinib might address a growing unmet need for alternative therapies for these patients. Funding: Loxo Oncology.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03349042
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, September 20, 2021 - 11:14:07 AM
Last modification on : Wednesday, October 20, 2021 - 3:19:38 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

`

Citation

Anthony Mato, Nirav Shah, Wojciech Jurczak, Chan Cheah, John Pagel, et al.. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet, Elsevier, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩. ⟨inserm-03349042⟩

Share

Metrics

Record views

37